Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Lee, J.U.; Shin, W.; Son, J.Y.; Yoo, K.-Y.; Heo, Y.-S. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int. J. Mol. Sci. 2017, 18, 228. https://doi.org/10.3390/ijms18010228
Lee JU, Shin W, Son JY, Yoo K-Y, Heo Y-S. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. International Journal of Molecular Sciences. 2017; 18(1):228. https://doi.org/10.3390/ijms18010228
Chicago/Turabian StyleLee, Jee U., Woori Shin, Ji Y. Son, Ki-Young Yoo, and Yong-Seok Heo. 2017. "Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases" International Journal of Molecular Sciences 18, no. 1: 228. https://doi.org/10.3390/ijms18010228


